What the Wegovy pill actually is
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist: a medicine that mimics a natural gut hormone the body releases after eating. Until recently, the weight-management version — sold under the Wegovy brand — existed only as a once-weekly injection. The Wegovy pill is the same molecule reformulated as a once-daily tablet with a 25 mg maintenance dose, and Novo Nordisk describes it as the first oral GLP-1 receptor agonist licensed for weight management in adults.[1] It has since been joined by a second: on 10 August 2026 the MHRA authorised Foundayo (orforglipron, Eli Lilly) as the UK's second oral GLP-1 licensed for weight management, and it has been available on private prescription since 24 August 2026.[9]
The Wegovy pill is oral semaglutide 25 mg — the same active ingredient as the injection, in a once-daily tablet. It is one option a prescriber may discuss for weight management, and it is prescription-only.
How the Wegovy pill works
As a GLP-1 receptor agonist, semaglutide acts on appetite-regulating areas of the brain: it increases fullness (satiety), reduces hunger and dampens food cravings, so most people eat less without consciously fighting their appetite.[2] Combined with a reduced-calorie diet and more activity, that drives the weight loss seen in the trials below.
The harder part is delivery. The tablet has to be taken to a strict routine: on an empty stomach with only a little water, and then a wait before eating, drinking anything else or taking other medicines.[2][10] Our dosage and how-to-take page sets out the tablet strengths and the daily routine in full, and our guide to how the Wegovy pill works explains the mechanism in more depth.
Wegovy pill vs Wegovy injection — and vs Rybelsus
Three different semaglutide products are easy to confuse, so it helps to line them up. The Wegovy injection and the Wegovy pill are the same medicine in two forms, for the same purpose. Rybelsus is a separate, lower-dose oral semaglutide licensed for a different condition — type 2 diabetes, not weight management.
| Product | Form & frequency | Licensed use | Dose |
|---|---|---|---|
| Wegovy injection | Subcutaneous injection, once weekly | Weight management[6] | 2.4 mg once weekly (maintenance)[2] |
| Wegovy pill | Oral tablet, once daily | Weight management[1] | 25 mg once daily (maintenance)[1] |
| Rybelsus | Oral tablet, once daily | Type 2 diabetes[5] | 1.5, 4 or 9 mg once daily (newer tablets that replaced 3, 7 and 14 mg)[5] |
Pill vs injection
The pill and the injection contain the same active ingredient, so the goal — appetite reduction leading to weight loss — is the same. What differs is the route and rhythm: a tablet swallowed once a day versus an injection under the skin once a week. The MHRA says that someone established on the 2.4 mg once-weekly injection can be moved directly onto the 25 mg once-daily tablet.[2] The two forms use different dose numbers, so their strengths cannot be compared like-for-like. Our pill vs injection comparison goes further.
Pill vs Rybelsus
This is the comparison people get wrong most often, because both are oral semaglutide made with the same absorption technology. The distinction is dose and purpose: Rybelsus is licensed for type 2 diabetes at 1.5, 4 or 9 mg once daily (newer tablets that replaced its 3, 7 and 14 mg strengths),[5] while the Wegovy pill is a higher-dose oral semaglutide — a 25 mg maintenance dose for weight management.[1] They are separate products with separate licences and dose ladders; even where the milligram numbers match, one is not a substitute for the other, and a prescriber chooses which, if either, is appropriate.
Is the Wegovy pill licensed in the UK?
Yes — with important caveats about how you can actually get it. The MHRA licensed oral semaglutide tablets for weight loss on 11 June 2026, making the Wegovy pill an approved medicine in the UK.[2] But an MHRA licence is not NHS availability: the MHRA said the tablet was not currently available on the NHS, and that decisions on NHS use would follow established processes, including an evaluation by NICE — the body that decides which treatments the NHS pays for.[2] That mirrors injectable semaglutide, which was appraised and then offered only to defined groups of patients.[6]
The United States is a step ahead: the US Food and Drug Administration approved the oral semaglutide 25 mg tablet on 22 December 2025 for weight management, and also to reduce the risk of major adverse cardiovascular events in certain adults with overweight or obesity and established cardiovascular disease.[1][8] In the European Union, the tablets have since been added to Wegovy's EU-wide authorisation, following a positive opinion from the European Medicines Agency's human medicines committee on 21 May 2026;[11] status elsewhere should be checked against the relevant regulator.
| Country / region | Status |
|---|---|
| United States (FDA) | Approved 22 December 2025 for weight management[1] |
| United Kingdom (MHRA) | Licensed 11 June 2026; not on the NHS at approval[2] |
| European Union (EMA) | Tablets added to Wegovy's EU-wide authorisation after a positive EMA committee opinion on 21 May 2026[11] |
What the OASIS trial found
The tablet's weight-management evidence comes from the OASIS programme of phase 3 trials. The study behind the approved 25 mg dose was OASIS 4, which ran for 64 weeks in adults with obesity, or overweight with weight-related complications, without type 2 diabetes, comparing the tablet against placebo alongside lifestyle support.[3]
OASIS 4 reported two headline figures, because trials measure effect in two ways. Among people who kept taking the tablet as intended, mean weight loss was about 16.6%, versus roughly 2.8% on placebo;[1][10] measured across everyone regardless of how consistently they took it, it was about 13.6%, versus 2.2% on placebo according to the UK product information.[10] Around 76% of people on the tablet lost at least 5% of their body weight, against about 31% on placebo, and roughly one in three reached a 20% loss on the fuller-adherence measure — a figure of about 28% when averaged across everyone.[1][8][10]
An earlier trial, OASIS 1, tested a higher 50 mg dose — not the strength that was licensed — and reported mean weight loss of 15.1% versus 2.4% on placebo at 68 weeks, published in The Lancet in 2023.[4] The on-label story, though, is OASIS 4 at 25 mg, published in the New England Journal of Medicine in September 2025.[3]
The 16.6% and 13.6% numbers are not a contradiction. One estimates the effect if a person keeps taking the medicine as intended; the other averages in everyone, including those who stopped or took it irregularly.
Side effects and safety
Like the injection, the tablet's most common side effects are gastrointestinal. In OASIS 4, gastrointestinal adverse events affected about 74% of people on oral semaglutide against 42% on placebo, and were mostly mild to moderate; the share who stopped because of side effects was similar for drug and placebo (about 7% versus 6%).[3][8] The US prescribing information lists the usual semaglutide effects — nausea, diarrhoea, vomiting, constipation, stomach pain, headache and tiredness among them —[8] and Novo Nordisk says the overall safety profile is comparable to earlier semaglutide weight-management trials.[1]
Semaglutide carries a boxed warning in the US about a risk of thyroid C-cell tumours, based on animal studies, and the US label says it should not be used by people with certain thyroid or endocrine conditions;[8] the UK product information lists only one formal contraindication, allergy to its ingredients, and says it should not be used in pregnancy or while breastfeeding.[10] These are decisions for a prescriber who knows your history. If you take any weight-loss medicine and experience side effects, report them through the MHRA Yellow Card scheme[7] and speak to your GP or pharmacist. Our side effects page covers the warnings in full.
How you would access it in the UK
The Wegovy pill is prescription-only: a prescriber decides whether it is appropriate, and only a GPhC-registered pharmacy can dispense it against a valid prescription after a consultation. It was not available on the NHS at approval.[2] A website selling semaglutide with no prescription or clinical assessment is not operating lawfully, and what it supplies may not be a genuine, regulated medicine. To read more first, see our frequently asked questions or the development story behind the tablet.
Frequently asked questions
What is the Wegovy pill?
It is a once-daily tablet form of semaglutide — a GLP-1 receptor agonist — taken for weight management at a 25 mg maintenance dose. It is the same active ingredient as the once-weekly injection, swallowed rather than injected, and it is prescription-only.[1]
Is the Wegovy pill the same as Rybelsus?
No. Both are oral semaglutide tablets, but they are different products for different jobs. Rybelsus is licensed for type 2 diabetes at 1.5, 4 or 9 mg once daily (newer tablets that replaced its 3, 7 and 14 mg strengths); the Wegovy pill is a higher-dose oral semaglutide, with a 25 mg maintenance dose, developed for weight management.[5][1]
Is the Wegovy pill available on the NHS?
Not at approval. The MHRA licensed the tablet on 11 June 2026 and said it was not currently available on the NHS; decisions on NHS use would follow established processes, including an evaluation by NICE.[2]
How much weight did people lose in the trials?
In OASIS 4, mean weight loss was about 16.6% among people who took oral semaglutide 25 mg as intended, and 13.6% regardless of adherence, versus roughly 2–3% on placebo over 64 weeks.[10]
Can I buy the Wegovy pill without a prescription?
No. It is prescription-only. Lawful UK supply happens only through a GPhC-registered pharmacy against a valid prescription, after a consultation, and only a prescriber can decide whether it is appropriate. A website offering it with no prescription or consultation is not operating lawfully.
Further reading
- How the Wegovy pill works: oral semaglutide explained
- Wegovy pill side effects: what the OASIS 4 trial and UK leaflet say
- Wegovy pill dosage steps: 1.5 mg to 25 mg, month by month
References
- Novo Nordisk. Wegovy pill (oral semaglutide 25 mg) — FDA approval announcement, including US indication, dosing and OASIS 4 results. novonordisk.com
- Medicines and Healthcare products Regulatory Agency (MHRA) / GOV.UK. "First GLP-1 tablet for weight loss approved in the UK" — press release, 11 June 2026: the UK licence, the mechanism (appetite regulation in the brain), the taking-it rules (on an empty stomach after fasting for at least 8 hours, with a sip of water, then no food or drink for at least 30 minutes), the direct switch from the 2.4 mg once-weekly injection to the 25 mg once-daily tablet, and the NHS position (not currently available on the NHS; decisions on NHS use to follow established processes, including a NICE evaluation). gov.uk
- Wharton S, Lingvay I, Bogdanski P, et al. "Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity" (OASIS 4). New England Journal of Medicine, 18 September 2025;393:1077–1087 — design, body-weight change at week 64 (−13.6% vs −2.2% with placebo) and gastrointestinal adverse events (74.0% vs 42.2%). doi.org/10.1056/NEJMoa2500969 Trial registration: ClinicalTrials.gov NCT05564117. clinicaltrials.gov
- The Lancet. OASIS 1: oral semaglutide 50 mg for weight management, 2023. thelancet.com
- Medicines and Healthcare products Regulatory Agency (MHRA). Drug Safety Update, "Rybelsus® (semaglutide tablets): transition to new formulation and risk of medication error", 17 December 2025 — Rybelsus is for adults with type 2 diabetes; new 1.5 mg, 4 mg and 9 mg tablets are bioequivalent to, and replace, the original 3 mg, 7 mg and 14 mg tablets. gov.uk
- National Institute for Health and Care Excellence. TA875: semaglutide for managing overweight and obesity (injectable form; context for the pill's likely NHS route). nice.org.uk
- MHRA. Yellow Card scheme — report a suspected side effect. yellowcard.mhra.gov.uk
- US Food and Drug Administration. Wegovy (semaglutide) injection and tablets — US Prescribing Information, revised 06/2026 (via DailyMed): US indications, including reducing the risk of major adverse cardiovascular events; the boxed warning on thyroid C-cell tumours and the contraindications; the common side-effect list; and the 25 mg tablet trial results (−13.6% body-weight change, at least 5% weight loss in 76.3% vs 31.3% on placebo, at least 20% in 27.9%, and 6.9% vs 5.9% stopping treatment because of adverse reactions). dailymed.nlm.nih.gov
- MHRA / GOV.UK. "UK first in Europe to authorise orforglipron for weight management and type 2 diabetes" — Foundayo (orforglipron) authorisation, 10 August 2026; Lilly UK announced private-prescription availability on 24 August 2026. gov.uk
- Novo Nordisk. Wegovy 25 mg tablets — UK Summary of Product Characteristics, section 4.2 (swallow whole on an empty stomach after fasting for at least 8 hours, with a sip of water, then wait at least 30 minutes before eating, drinking or taking other oral medicines), section 4.3 (hypersensitivity to semaglutide or any excipient is the only contraindication), section 4.6 (not to be used in pregnancy or breast-feeding) and section 5.1, Table 2 (OASIS 4 results at week 64: body-weight change −13.6% vs −2.2% with placebo, and ≥20% weight loss in 27.5% vs 3%, treatment-policy analysis; −16.6% vs −2.8% if all patients had stayed on treatment); text revised 06/2026. medicines.org.uk
- European Medicines Agency. Wegovy — EPAR overview and assessment history: the EU medicine overview (updated 26 August 2026) now covers tablets as well as pens; CHMP post-authorisation summary of positive opinion for the tablet extension (X/0000296344), adopted 21 May 2026, with the European Commission decision issued on 14 July 2026. ema.europa.eu